CompletedNCT07018245
Clinical Trial of TJ0113 Capsules in the Treatment of Patients With Depressive Disorder
Medication studyAges 18–65ChinaDepression
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- HangzhouSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: July 9, 2025
- Recruitment status
- Completed
- Enrollment listed in the registry
- 149
- Sponsor
- Hangzhou PhecdaMed Co., Ltd.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- China
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07018245
- Official title
Show the full official title
A Phase II, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-GroupClinical Trial to Evaluate the Safety and Efficacy of TJ0113 Capsules in Patients withDepressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Hangzhou
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Hangzhou PhecdaMed Co., Ltd.
Did this study involve medication?
Yes. The study involved medication, including TJ0113 and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
